Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth.

N/ACompletedNCT01962077

Hadassah Medical Organization60 enrolled

Overview

assess the effect of MedCem MTA as a pulp medicament following pulpotomy in human primary molars with carious pulp exposure in comparison to Formocresol.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pulpotomies Primary Teeth Effectiveness of MedCem MTA® in Pulpotomies Primary Teeth

Interventions

MedCem MTA pulpotomies in primary teeth.PROCEDURE

Eligibility

Sex: ALLMin age: 2 YearsMax age: 10 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. healthy children 2. with Asymptomatic primary molars with a deep carious lesion; 3. Exposure of a vital pulp by caries; 4. No clinical or radiographic evidence of pulp degeneration, such as excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction,swelling, or sinus tract; 5. Ability to perform a leakage free restoration of the teeth using stainless steel crown, or amalgam/resin based restoration.

Locations (1)

Hadassah Medical Organization

Jerusalem, Israel

Outcomes

Primary Outcomes

Success of MedCem MTA pulpotomy in primary molar

No pain, no swelling or sinus tract, no internal root resorption progressing into the bone, no furcation and/or periapical bond destruction.

Time frame: Up to 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.